The Prognostic Value of One-Step Nucleic Acid Amplification (OSNA) and Immunohistochemistry (IHC) in Ex Vivo Sentinel Lymph Nodes in Stage I & II Colonic Cancer Patients - A Multicenter Cohort Study Volume 3 - Issue 4

RLA van der Linden¹*, JC van der Linden², FJ Vogelaar³, DJ Lips¹, CJH van de Velde⁴ and K Bosscha¹

• ¹Department of Surgery, Jeroen Bosch Hospital, Netherlands
• ²Department of Pathology, Jeroen Bosch Hospital, Netherlands
• ³Department of Surgery, Vie Curi Medical Center, Netherlands
• ⁴Department of Surgery, Leiden University Medical Center, Netherlands

Received:April 06, 2020   Published: April 16, 2020

Corresponding author: RLA van der Linden, Department of Surgery, Jeroen Bosch Hospital, ‘s-Hertogenbosch, the Netherlands

DOI: 10.32474/OAJOM.2020.03.000169

 

Fulltext PDF

To view the Full Article   Peer-reviewed Article PDF

Abstract

Introduction: Sentinel lymph node (SLN) mapping with multilevel-sectioning and immunohistochemistry (IHC) or One- Step Nucleic Acid Amplification (OSNA) are considered promising techniques to improve LN staging in colon cancer. This study investigates the prognostic significance of OSNA- and IHC-analysis of ex vivo SNLs of stage I&II colon cancer patients.

Methods: 86 stage I&II colon cancer patients were identified from two previously conducted cohort studies. All SLNs were examined with Hematoxylin & Eosin-staining (H&E), multilevel-sectioning with IHC and OSNA analysis. Kaplan-Meier and coxregression analysis were performed to determine the prognostic significance.

Results: Mean disease-free survival (DFS) for OSNA-positive vs OSNA-negative patients was 62.5 vs 62.0 months (p=0.886) and for IHC-positive vs IHC-negative patients 58.1 vs 62.9 months (p=0.519). Cox-regression analysis showed that positive OSNAstatus was not prognostic for DFS (hazard ratio (HR)=0.89, p=0.886). Additionally, also positive IHC-status showed no significant difference for DFS (HR 1.47, p=0.522).

Conclusions: Additional OSNA or IHC-analysis of ex vivo SLNs does not provide a more accurate prognostic value in this small group of stage I&II colon cancer patients compared with conventional H&E. A bigger study is needed to set these results in a broader perspective. Further research is required to identify other clinically relevant upstaging techniques and prognostic factors to tailor the treatment plans of these patients.

Abstract| Introduction| Material and Methods| Results| Discussion| Acknowledgement| Statement of Ethics and Funding Sources| References|